Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome
Conditions
Interventions
lademirsen (SAR339375)
Placebo
Locations
23
United States
Investigational Site Number :8400002
Los Angeles, California, United States
University of Minnesota Childrens' Hospital_Investigational Site Number :8400003
Minneapolis, Minnesota, United States
Columbia University Medical Center_Investigational Site Number :8400004
New York, New York, United States
The Cleveland Clinic Foundation_Investigational Site Number :8400001
Cleveland, Ohio, United States
University of Utah_Investigational Site Number :8400005
Salt Lake City, Utah, United States
Investigational Site Number :0360003
Herston, Queensland, Australia
Start Date
November 2, 2019
Primary Completion Date
September 22, 2022
Completion Date
September 22, 2022
Last Updated
September 11, 2025
NCT06499948
NCT06065852
NCT04947813
NCT06226896
NCT00481130
NCT02136862
Lead Sponsor
Genzyme, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions